Guangwei Shi

China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Corrigendum to 'Reprogramming tumor microenvironment with precise photothermal therapy by calreticulin nanobody-engineered probiotics' [Biomaterials 314 (2015) 122809].

Corrigendum to 'Reprogramming tumor microenvironment with precise photothermal therapy by calreticulin nanobody-engineered probiotics' [Biomaterials 314 (2015) 122809].

Journal: Biomaterials

Published: August 27, 2025

Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies.

Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies.

Journal: Journal of nanobiotechnology

Published: February 19, 2025

Targeting RAGE with Nanobodies for Molecular Imaging of Cancers and Alzheimer's Disease.

Targeting RAGE with Nanobodies for Molecular Imaging of Cancers and Alzheimer's Disease.

Journal: Advanced biology

Published: October 15, 2024

GRP78 Nanobody-Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy.

GRP78 Nanobody-Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 15, 2024

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin.

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin.

Journal: Journal for immunotherapy of cancer

Published: June 13, 2024

CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers.

CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers.

Journal: Acta pharmaceutica Sinica. B

Published: May 16, 2024

Reprogramming tumor microenvironment with precise photothermal therapy by calreticulin nanobody-engineered probiotics.

Reprogramming tumor microenvironment with precise photothermal therapy by calreticulin nanobody-engineered probiotics.

Journal: Biomaterials

Published: March 31, 2024

Probiotic-mediated tumor microenvironment reprogramming with protease-sensitive interleukin-15 and photothermal therapy.

Probiotic-mediated tumor microenvironment reprogramming with protease-sensitive interleukin-15 and photothermal therapy.

Journal: Cell reports. Medicine

Published: March 17, 2024

Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer.

Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer.

Journal: Biomaterials research

Published: January 29, 2024

Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.

Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.

Journal: ACS nano

Published: January 22, 2024

A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant.

A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant.

Journal: Journal of medical virology

Published: December 19, 2023

Erratum: Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells.

Erratum: Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells.

Journal: Molecular therapy. Nucleic acids

Published: August 14, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026